Heart failure is an increasing public health issue with substantial morbidity and mortality rates. This study aimed to evaluate the efficacy, safety, and long-term outcomes of angiotensin receptor neprilysin inhibitor (ARNi) in the treatment of heart failure with reduced ejection fraction (HFrEF) 5 years after treatment initiation. This retrospective study analyzed a cohort of 75 patients diagnosed with HFrEF over a period of 5 years after the initiation of ARNi therapy. The initial clinical condition, laboratory and echocardiographic measurements including left ventricular ejection fraction (LVEF), New York Heart Association functional classes (NYHA-FC) and the prognostic nutritional index were compared to the corresponding values obtained after a 5-year period of ARNi therapy. In addition, the number of annual hospitalizations, mortality rates and any history of adverse effects during the follow-up period were recorded. The N-terminal pro-brain natriuretic peptide (NT-proBNP) level, LVEF, and NYHA-FC values demonstrated significant improvement at the end of the 5-year follow-up period (all parameters, P < .001). Although the observed increase in the prognostic nutritional index was not statistically significant (P = .077), it is worth noting. A significant reduction in daily diuretic doses and hospitalizations due to heart failure was observed following the use of ARNi (all comparisons, P < .001). The prevalence of hypotension was around 16% (being symptomatic in 4%), making it the most frequently observed adverse event. The 5-year cardiovascular mortality rate was 17.3%. The use of ARNi in HFrEF patients was associated with a notable improvement in NYHA-FC, LVEF, and NT-proBNP levels in the long-term, while also leading to a better nutritional status and reduced need for diuretics and annual hospitalization. Additionally, ARNi usage has been associated with improved nutritional status, decreased reliance on diuretics, and reduced frequency of annual hospitalizations. These effects were associated with a lack of significant increase in adverse effects. These results may contribute to a better understanding of ARNi’s long-term effects on patient outcomes.
21 August 2023 in Aging Clinical and Experimental Research
Postoperative atrial fibrillation (POAF) is associated with an increased risk of morbidity and mortality. This study aims to investigate the predictive value of uric acid/albumin ratio (UAR) for POAF following isolated coronary artery bypass grafting (CABG). This retrospective study screened patients who underwent isolated CABG between June 2017 and January 2024. POAF was diagnosed using standard clinical criteria. UAR was calculated by dividing the uric acid level by the albumin value. This study included a total of 396 patients, who were categorized into two groups: POAF- and POAF+. Among them, 321 patients (mean age: 61.7 ± 10.8 years; 74.7% male) belonged to the POAF- group, while 75 patients (mean age: 71.3 ± 10.04 years; 68.1% male) were in the POAF+ group. While there were no significant differences observed between the groups in terms of sex, those in the POAF+ group were statistically older. The univariate and multivariate regression analyses revealed that age, C-reactive protein, hypertension, serum uric acid level, and UAR are independent risk factors for POAF. In the receiver operating characteristics analysis, the UAR (area under the curve [AUC]: 0.775) was found to be a better indicator compared to uric acid (AUC: 0.649) and serum albumin (AUC: 0.606), with a sensitivity of 70.5% and a specificity of 69.2%. UAR was shown to be an independent risk factor for POAF following isolated CABG.